Katherine L. Gudiksen is a senior research fellow at the Source on Healthcare Price and Competition, University of California Hastings College of the Law, in San Francisco.
Timothy T. Brown is an associate professor of health economics, School of Public Health, University of California Berkeley.
Health Aff (Millwood). 2018 Sep;37(9):1503-1508. doi: 10.1377/hlthaff.2018.0424.
The California drug transparency bill (SB-17), signed into law in October 2017, seeks to promote transparency in pharmaceutical pricing, enhance understanding about pharmaceutical pricing trends, and assist in managing pharmaceutical costs. This article examines the legal and regulatory aspects of SB-17, explores legal challenges to the law, compares it to other state efforts to address rising drug prices, and discusses how California can maximize the impact of SB-17 by coupling the law with other incentives. While SB-17 might not significantly reduce drug prices, the new law represents a meaningful step for one state seeking to negotiate the political and legal boundaries of state action to rein in drug prices.
加利福尼亚州药品透明度法案（SB-17）于 2017 年 10 月签署成为法律，旨在提高药品定价透明度、增进对药品定价趋势的了解，并帮助控制药品成本。本文探讨了 SB-17 的法律和监管方面，分析了该法律面临的法律挑战，将其与其他州为解决药品价格上涨所做的努力进行了比较，并讨论了加利福尼亚州如何通过将该法律与其他激励措施相结合，最大限度地发挥 SB-17 的影响。虽然 SB-17 可能不会显著降低药品价格，但该新法是一个州在寻求谈判州级行动以控制药品价格的政治和法律界限方面迈出的有意义的一步。
